Revolution Stock Based Compensation vs End Period Cash Flow Analysis

RVMDW Stock

0.35 0.01 2.94%

Revolution Medicines, financial indicator trend analysis is much more than just breaking down Revolution Medicines, prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Revolution Medicines, is a good investment. Please check the relationship between Revolution Medicines, Stock Based Compensation and its End Period Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines, Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Stock Based Compensation vs End Period Cash Flow

Stock Based Compensation vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Revolution Medicines, Stock Based Compensation account and End Period Cash Flow. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Revolution Medicines,'s Stock Based Compensation and End Period Cash Flow is 0.98. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Revolution Medicines, Warrant, assuming nothing else is changed. The correlation between historical values of Revolution Medicines,'s Stock Based Compensation and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Revolution Medicines, Warrant are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Stock Based Compensation i.e., Revolution Medicines,'s Stock Based Compensation and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.98

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

End Period Cash Flow

Most indicators from Revolution Medicines,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Revolution Medicines, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines, Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Sales General And Administrative To Revenue is likely to climb to 6.86 in 2024, whereas Tax Provision is likely to drop (3.7 M) in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	929K	9.2M	47.5M	49.9M
Net Interest Income	917K	9.2M	47.2M	49.5M

Interest Income Net Interest Income

Revolution Medicines, fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Good Will	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Non Current Liabilities Other	Net Working Capital	Intangible Assets	Short Long Term Debt Total
Total Assets		1.0	0.93	1.0	0.85	-0.98	0.98	0.99	0.86	0.15	-0.98	-0.91	0.92	1.0	0.74	0.84	1.0	0.9	0.99	0.85	1.0	-0.78	0.62	1.0	-0.88	0.89
Other Current Liab	1.0		0.92	1.0	0.86	-0.98	0.97	0.99	0.87	0.11	-0.99	-0.89	0.92	1.0	0.76	0.85	0.99	0.9	1.0	0.87	1.0	-0.81	0.62	1.0	-0.87	0.89
Total Current Liabilities	0.93	0.92		0.93	0.64	-0.89	0.98	0.97	0.65	0.4	-0.87	-0.93	0.8	0.91	0.45	0.62	0.95	0.76	0.89	0.65	0.94	-0.54	0.67	0.93	-0.83	0.72
Total Stockholder Equity	1.0	1.0	0.93		0.85	-0.98	0.98	0.99	0.86	0.16	-0.98	-0.91	0.92	1.0	0.74	0.84	1.0	0.9	0.99	0.85	1.0	-0.77	0.63	1.0	-0.88	0.89
Property Plant And Equipment Net	0.85	0.86	0.64	0.85		-0.91	0.74	0.78	1.0	-0.29	-0.92	-0.56	0.96	0.87	0.92	1.0	0.84	0.95	0.9	1.0	0.84	-0.93	0.43	0.84	-0.63	0.97
Retained Earnings	-0.98	-0.98	-0.89	-0.98	-0.91		-0.95	-0.96	-0.91	-0.04	0.99	0.83	-0.95	-0.98	-0.77	-0.89	-0.98	-0.93	-0.98	-0.91	-0.98	0.81	-0.55	-0.98	0.84	-0.94
Accounts Payable	0.98	0.97	0.98	0.98	0.74	-0.95		1.0	0.76	0.33	-0.93	-0.94	0.86	0.97	0.61	0.73	0.98	0.84	0.95	0.75	0.98	-0.63	0.68	0.98	-0.87	0.83
Cash	0.99	0.99	0.97	0.99	0.78	-0.96	1.0		0.8	0.27	-0.95	-0.93	0.89	0.98	0.66	0.77	0.99	0.87	0.97	0.79	0.99	-0.7	0.68	0.99	-0.87	0.85
Non Current Assets Total	0.86	0.87	0.65	0.86	1.0	-0.91	0.76	0.8		-0.26	-0.92	-0.6	0.95	0.89	0.95	1.0	0.85	0.94	0.91	0.99	0.85	-0.92	0.43	0.86	-0.67	0.97
Non Currrent Assets Other	0.15	0.11	0.4	0.16	-0.29	-0.04	0.33	0.27	-0.26		0.03	-0.42	-0.07	0.11	-0.31	-0.32	0.16	-0.01	0.03	-0.28	0.17	0.49	0.58	0.16	-0.15	-0.08
Net Receivables	-0.98	-0.99	-0.87	-0.98	-0.92	0.99	-0.93	-0.95	-0.92	0.03		0.83	-0.95	-0.99	-0.8	-0.91	-0.98	-0.92	-1.0	-0.92	-0.98	0.87	-0.53	-0.98	0.85	-0.93
Good Will	-0.91	-0.89	-0.93	-0.91	-0.56	0.83	-0.94	-0.93	-0.6	-0.42	0.83		-0.67	-0.89	-0.49	-0.55	-0.91	-0.64	-0.86	-0.57	-0.91	0.52	-0.54	-0.91	0.95	-0.66
Common Stock Shares Outstanding	0.92	0.92	0.8	0.92	0.96	-0.95	0.86	0.89	0.95	-0.07	-0.95	-0.67		0.93	0.82	0.94	0.92	0.99	0.94	0.96	0.92	-0.84	0.63	0.92	-0.65	0.95
Short Term Investments	1.0	1.0	0.91	1.0	0.87	-0.98	0.97	0.98	0.89	0.11	-0.99	-0.89	0.93		0.77	0.86	0.99	0.91	1.0	0.88	1.0	-0.81	0.6	1.0	-0.87	0.91
Non Current Liabilities Total	0.74	0.76	0.45	0.74	0.92	-0.77	0.61	0.66	0.95	-0.31	-0.8	-0.49	0.82	0.77		0.94	0.7	0.85	0.79	0.92	0.73	-0.88	0.35	0.74	-0.58	0.9
Capital Lease Obligations	0.84	0.85	0.62	0.84	1.0	-0.89	0.73	0.77	1.0	-0.32	-0.91	-0.55	0.94	0.86	0.94		0.82	0.94	0.89	1.0	0.83	-0.94	0.41	0.83	-0.63	0.96
Other Current Assets	1.0	0.99	0.95	1.0	0.84	-0.98	0.98	0.99	0.85	0.16	-0.98	-0.91	0.92	0.99	0.7	0.82		0.89	0.99	0.84	1.0	-0.76	0.62	1.0	-0.88	0.88
Total Liab	0.9	0.9	0.76	0.9	0.95	-0.93	0.84	0.87	0.94	-0.01	-0.92	-0.64	0.99	0.91	0.85	0.94	0.89		0.91	0.95	0.9	-0.8	0.69	0.9	-0.61	0.96
Net Invested Capital	0.99	1.0	0.89	0.99	0.9	-0.98	0.95	0.97	0.91	0.03	-1.0	-0.86	0.94	1.0	0.79	0.89	0.99	0.91		0.9	0.99	-0.85	0.57	0.99	-0.86	0.91
Property Plant And Equipment Gross	0.85	0.87	0.65	0.85	1.0	-0.91	0.75	0.79	0.99	-0.28	-0.92	-0.57	0.96	0.88	0.92	1.0	0.84	0.95	0.9		0.84	-0.92	0.44	0.85	-0.63	0.97
Total Current Assets	1.0	1.0	0.94	1.0	0.84	-0.98	0.98	0.99	0.85	0.17	-0.98	-0.91	0.92	1.0	0.73	0.83	1.0	0.9	0.99	0.84		-0.76	0.64	1.0	-0.88	0.89
Capital Stock	-0.78	-0.81	-0.54	-0.77	-0.93	0.81	-0.63	-0.7	-0.92	0.49	0.87	0.52	-0.84	-0.81	-0.88	-0.94	-0.76	-0.8	-0.85	-0.92	-0.76		-0.23	-0.77	0.65	-0.82
Non Current Liabilities Other	0.62	0.62	0.67	0.63	0.43	-0.55	0.68	0.68	0.43	0.58	-0.53	-0.54	0.63	0.6	0.35	0.41	0.62	0.69	0.57	0.44	0.64	-0.23		0.63	-0.29	0.52
Net Working Capital	1.0	1.0	0.93	1.0	0.84	-0.98	0.98	0.99	0.86	0.16	-0.98	-0.91	0.92	1.0	0.74	0.83	1.0	0.9	0.99	0.85	1.0	-0.77	0.63		-0.88	0.89
Intangible Assets	-0.88	-0.87	-0.83	-0.88	-0.63	0.84	-0.87	-0.87	-0.67	-0.15	0.85	0.95	-0.65	-0.87	-0.58	-0.63	-0.88	-0.61	-0.86	-0.63	-0.88	0.65	-0.29	-0.88		-0.69
Short Long Term Debt Total	0.89	0.89	0.72	0.89	0.97	-0.94	0.83	0.85	0.97	-0.08	-0.93	-0.66	0.95	0.91	0.9	0.96	0.88	0.96	0.91	0.97	0.89	-0.82	0.52	0.89	-0.69

Click cells to compare fundamentals

Revolution Medicines, Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Revolution Stock Analysis

When running Revolution Medicines,'s price analysis, check to measure Revolution Medicines,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines, is operating at the current time. Most of Revolution Medicines,'s value examination focuses on studying past and present price action to predict the probability of Revolution Medicines,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines,'s price. Additionally, you may evaluate how the addition of Revolution Medicines, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Revolution Stock Based Compensation vs End Period Cash Flow Analysis

Stock Based Compensation vs End Period Cash Flow

Stock Based Compensation vs End Period Cash Flow Correlation Analysis

Correlation Coefficient

Stock Based Compensation

End Period Cash Flow

Revolution Medicines, fundamental ratios Correlations

Revolution Medicines, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Revolution Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Liab	+ 1.0	Total Assets
Total Stockholder Equity	+ 1.0	Total Assets
Short Term Investments	+ 1.0	Total Assets
Other Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets

Net Invested Capital	- 1.0	Net Receivables
Short Term Investments	- 0.99	Net Receivables
Net Receivables	- 0.99	Other Current Liab
Net Working Capital	- 0.98	Net Receivables
Total Current Assets	- 0.98	Net Receivables
Other Current Assets	- 0.98	Net Receivables